The use of tissue- or tumor-selective promoters in targeted gene therapy for prostate cancer depends on strong and selective activity. The -426 to +28 bp probasin (PB) promoter has the potential to target selected genes to the prostatic epithelial cells. We showed that in the assay of luciferase reporter gene driven by PB promoter, activation of luciferase expression was 1.5-fold increase in human prostate cancer cell LNCaP relative to non-small cell lung cancer cell H460. Significant increase of luciferase activity was observed in both cell lines when infection with ICP27 (-) HSV-1 was added to PBluciferase plasmid transfected LNCaP and H460 cells. In addition, an expression vector (PB-ICP27) was generated in which one of the herpe...
BACKGROUND: Hepatocellular carcinoma (HCC) is a cancer of poor prognosis, with limited success in pa...
Prostate cancer is the second leading cause of cancer related deaths in males. There is no current c...
It is known that the probasin (PB) promoter has the ability to dictate prostatespecific gene express...
The use of tissue- or tumor-selective promoters in targeted gene therapy for prostate cancer depend...
Prostate cancer is the most common non-skin cancer, and the second leading cause of cancer-death in ...
Oncolytic herpes simplex viruses type 1 (oHSVs) such as G47Δ and G207 are genetically engineered for...
The Escherichia coli enzyme (purine nucleoside phosphorylase, PNP) gene is delivered directly into P...
Advanced prostate cancer is invariably lethal once it becomes androgen independent (AI). With the ai...
<div><p>Gene therapy represents an attractive strategy for the non-invasive treatment of prostate ca...
Gene therapy represents an attractive strategy for the non-invasive treatment of prostate cancer, wh...
Viral gene therapy against malignant tumors holds great promise for tumors that are susceptible to t...
Viral gene therapy against malignant tumors holds great promise for tumors that are susceptible to t...
Abstract Gene products that are only expressed in one tissue or cell type are useful models for inve...
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death...
The inability of replication-defective viral vectors to efficiently transduce tumor cells in vivo ha...
BACKGROUND: Hepatocellular carcinoma (HCC) is a cancer of poor prognosis, with limited success in pa...
Prostate cancer is the second leading cause of cancer related deaths in males. There is no current c...
It is known that the probasin (PB) promoter has the ability to dictate prostatespecific gene express...
The use of tissue- or tumor-selective promoters in targeted gene therapy for prostate cancer depend...
Prostate cancer is the most common non-skin cancer, and the second leading cause of cancer-death in ...
Oncolytic herpes simplex viruses type 1 (oHSVs) such as G47Δ and G207 are genetically engineered for...
The Escherichia coli enzyme (purine nucleoside phosphorylase, PNP) gene is delivered directly into P...
Advanced prostate cancer is invariably lethal once it becomes androgen independent (AI). With the ai...
<div><p>Gene therapy represents an attractive strategy for the non-invasive treatment of prostate ca...
Gene therapy represents an attractive strategy for the non-invasive treatment of prostate cancer, wh...
Viral gene therapy against malignant tumors holds great promise for tumors that are susceptible to t...
Viral gene therapy against malignant tumors holds great promise for tumors that are susceptible to t...
Abstract Gene products that are only expressed in one tissue or cell type are useful models for inve...
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death...
The inability of replication-defective viral vectors to efficiently transduce tumor cells in vivo ha...
BACKGROUND: Hepatocellular carcinoma (HCC) is a cancer of poor prognosis, with limited success in pa...
Prostate cancer is the second leading cause of cancer related deaths in males. There is no current c...
It is known that the probasin (PB) promoter has the ability to dictate prostatespecific gene express...